Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 34, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2022-12-22
DOI
10.1080/09546634.2022.2161812
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- (2023) Brett King et al. BRITISH JOURNAL OF DERMATOLOGY
- Recent issues in JAK inhibitor safety: perspective for the clinician
- (2022) Roy Fleischmann Expert Review of Clinical Immunology
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate‐to‐Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo‐Controlled , Phase III Clinical Trial ( BREEZE‐AD4 )
- (2022) Thomas Bieber et al. BRITISH JOURNAL OF DERMATOLOGY
- An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate‐to‐severe atopic dermatitis
- (2022) T. Werfel et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
- (2022) Thomas Bieber et al. ADVANCES IN THERAPY
- Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5)
- (2021) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The incidence and clinical analysis of non-melanoma skin cancer
- (2021) Magdalena Ciążyńska et al. Scientific Reports
- Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
- (2021) Brett King et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
- (2021) Kristin J. Meyers et al. Dermatology and Therapy
- Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
- (2021) Eric L. Simpson et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population‐based cohort study
- (2021) J. Wan et al. BRITISH JOURNAL OF DERMATOLOGY
- The infection risks of JAK inhibition
- (2021) Maryam A. Adas et al. Expert Review of Clinical Immunology
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- Association of herpes zoster and chronic inflammatory skin disease in US inpatients
- (2020) Raj Chovatiya et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
- (2020) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study
- (2020) Catherine Droitcourt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Association Between Atopic Eczema and Cancer in England and Denmark
- (2020) Kathryn E. Mansfield et al. JAMA Dermatology
- A Call to Standardise the BCC:SCC Ratio
- (2020) Z. Jiyad et al. BRITISH JOURNAL OF DERMATOLOGY
- Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
- (2020) T. Bieber et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Atopic dermatitis and cardiovascular disease: what are the clinical implications?
- (2019) Aaron M. Drucker et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
- (2019) Lawrence F. Eichenfield et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Conjunctivitis in dupilumab clinical trials
- (2019) B. Akinlade et al. BRITISH JOURNAL OF DERMATOLOGY
- Recurrent Eczema Herpeticum ‐ A Retrospective European Multicenter Study Evaluating the Clinical Characteristics of Eczema Herpeticum Cases in Atopic Dermatitis Patients
- (2019) Marlene Seegräber et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults
- (2018) Shanthi Narla et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study
- (2018) Richard J Silverwood et al. BMJ-British Medical Journal
- Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study
- (2018) Richard J Silverwood et al. BMJ-British Medical Journal
- Increased Risk of Cutaneous and Systemic Infections in Atopic Dermatitis—A Cohort Study
- (2017) Sinéad M. Langan et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age
- (2017) Harvind S. Chahal et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis
- (2017) Jacob P. Thyssen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review
- (2016) Peck Y. Ong et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis
- (2016) Yuki M.F. Andersen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis
- (2016) Sara Gandini et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis
- (2015) Laureline Legendre et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Atopic keratoconjunctivitis: A review
- (2013) Joseph J. Chen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Atopic Dermatitis and Risk of Skin Cancer
- (2011) Annette O. Jensen et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K.
- (2010) A. Arana et al. BRITISH JOURNAL OF DERMATOLOGY
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- Phenotype of atopic dermatitis subjects with a history of eczema herpeticum
- (2009) Lisa A. Beck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now